SOPHiA GENETICS S.A. cash flow to debt ratio of -60.32% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

SOPHiA GENETICS S.A.'s free cash flow has increased -24.34% from $-51.00M last year to $-38.59M, signaling increasing performance

SOPHiA GENETICS S.A.'s debt to equity ratio is 1.37, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

SOPHiA GENETICS S.A.'s debt has increased relative to shareholder equity from 0.31 last year to 1.37 today, signaling weakened financials

SOPHiA GENETICS S.A. has negative EBITDA, making leverage ratio unreliable

SOPHiA GENETICS S.A.'s interest coverage ratio is -12.90, which means that the company struggles to meet interest obligations, signaling financial risk.

SOPHiA GENETICS S.A.'s profit margin has decreased (3.97%) in the last year from -95.89% to -99.70%, signaling decreasing performance

SOPHiA GENETICS S.A.'s short-term assets of $99.08M exceed its short-term liabilities of $50.53M

SOPHiA GENETICS S.A.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

SOPHiA GENETICS S.A.'s return on equity of -140.63%, is lower than 15.00%, indicating bad performance

SOPHiA GENETICS S.A.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

SOPHiA GENETICS S.A. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

SOPHiA GENETICS S.A. has negative free cash flow, indicating the company is burning cash rather than generating it

SOPHiA GENETICS S.A. has negative free cash flow, indicating cash burn

SOPHiA GENETICS S.A.'s yearly earnings has decreased 26.41% since last year from $-62.49M to $-79.00M, signaling decreasing performance

SOPHiA GENETICS S.A.'s yearly revenue has increased 18.56% since last year from $65.17M to $77.27M, signaling increasing performance

ROIC -63.43% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

SOPHiA GENETICS S.A.'s 3-year revenue CAGR of 17.56% is positive, indicating growing revenue over the past 3 years

SOPHiA GENETICS S.A. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

SOPHiA GENETICS S.A. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

SOPHiA GENETICS S.A. has insufficient data to evaluate this check.

SOPHiA GENETICS S.A. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

SOPHiA GENETICS S.A. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

SOPHiA GENETICS S.A. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

SOPHiA GENETICS S.A. is overvalued relative to its fair value price of -26.57 based on Earnings Fair Value model

SOPHiA GENETICS S.A. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

SOPHiA GENETICS S.A. has a price-to-book ratio of 8.84x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

SOPHiA GENETICS S.A. has a price-to-sales ratio of 4.98x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue